PepChile

Salud Sexual y Reproductiva con Péptidos

Categorías: Guías Prácticas, Optimización Hormonal

Disfunción sexual (ED, bajo libido, anorgasmia) afecta 25-50% población, causando distress relacional. Péptidos ofrecen mecanismos novedosos: melanocortin signaling (PT-141), neuromodulation (oxitocina), hormonal optimization (HCG, GnRH).

Resumen Simplificado

PT-141 (melanocortin agonista) 0.5-1mg pre-coito (estimula sexual arousal centrally, trabaja ambos hombres+mujeres, no hormonalmente mediado). Oxitocina 5-10 IU intranasal (enhances bonding, orgasm intensity, satisfaction). HCG 250 IU diario (testosterona optimization, hombres). GnRH pulso 0.1-0.5 mcg (LH/FSH restoration, fertilidad). Monitoreo: testosterona baseline, arousal subjective, orgasm latency/intensity, pareja satisfaction.

PT-141 (Bremelanotide): Central Melanocortin Activation for Sexual Arousal

PT-141 es synthetic α-melanocyte–stimulating hormone (α-MSH) analog; activates melanocortin-4 receptors (MC4R) brain (hypothalamus—sexual arousal center). MECANISME: MC4R activation → sexual desire increase, physiological arousal (erection, vaginal lubrication), orgasm facilitation. NON-HORMONAL: tidak affect testosterona, estrógeno, LH, FSH—purely neuronal mechanism, ambos hombres + mujeres respond. INDIKASI: erectile dysfunction (ED), female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD)—especialmente situasi non-hormonal etiology (psicosexual, relación stress, trauma, medication side-effect). DOSIS: 0.5-1.0mg subcutaneous 30-45 minuto pre-coito; OR intranasal 0.5-1mg (menos data pero investigational). ONSET AKSI: 15-30 minuto (faster ED drugs seperti sildenafil 30-60 minuto). DURASI: 4-6 jam típicamente. EFEKTIVITAS: ED 65-75% responder (vs. sildenafil 70-80%), tapi PT-141 advantage = psicosexual-friendly (libido improvement, desire restoration—not just mechanical erection). FEMALE AROUSAL: 70-80% improvement sexual desire, arousal, orgasm frequency—especialmente HSDD + aging (estrogen deficiency). SIDE EFFECTS: facial flushing (melanin production related, cosmetic issue—dark-skin individuals dark pigmentation), nausea (gastrointestinal effect minority), headache. CONTRAINDICATIONS: uncontrolled hypertension (melanocortin activation sympathetic), cardiac arrhythmia (tachycardia risk), cutaneous melanoma (mel anoma risk theoretically—melanocortin involved, pero data non-conclusive). PHARMACY ACCESS: FDA approved (USA) 2019 nama Vylessi (expensive, $1300+ per injection kit). Peptido compounded farmacies cheaper alternativa.

Oxytocin Intranasal: Bonding, Orgasm Intensity, Sexual Satisfaction

OXITOCINA: neuropeptido synthesized hypothalamus, released pituitary posterior; orgasm, bonding, social behavior, affiliation. MECANISME SEXUAL: (1) orgasm amplification (oxytocin release during orgasm amplifies contractions, pleasure perception); (2) post-orgasm bonding enhancement (oxytocin mediate pair-bonding, satisfaction); (3) partner perception improvement (oxytocin increase trust, attractiveness perception). DOSIS SEXUAL: 5-10 IU intranasal 15-30 minuto pre-coito (o durante sexual activity). EFEK ESPERADO: orgasm latency reduction (faster climax), orgasm intensity 20-30% improvement (subjective pero measurable vaginal/penile contraction frequency), post-orgasm satisfaction 40-50% improvement (bonding feeling, emotional closeness). SINERGIA PARTNER: oxytocin intranasal both partners pre-coito = synchronized oxytocin peak, enhanced synchrony intimate experience (speculative neurologically, pero pareja testimonial supportive). DOSIS NON-SEXUAL: oxytocin 10-20 IU intranasal diario (baseline relationship bonding, anxiety reduction, social anxiety improvement—neuroscience data strong). SINERGIA PT-141 + OXITOCIN: PT-141 = desire + arousal (neuronal), oxytocin = orgasm + bonding (hormonal-neuronal). Kombinasi pre-coito = comprehensive sexual enhancement (desire + pleasure + bonding). TIMELINE BONDING EFEK: acute efek orgasm 2-4 minuto (oxytocin release immediate durante climax). Long-term relationship bonding: oxytocin diario baseline 4-8 minggu (pair-bonding, attachment security measurable psychological questionnaire). CAUTIONS: oxytocin dependency theoretical (receptor downregulation jika continuous high-dose, tapi intranasal standard dosis low-risk). Sex-specific RESPONSES: wanita typically respond lebih pronounced oxytocin effect (evolutionary bonding emphasis), pria response variable (some strong, some minimal—androgen/oxytocin receptor interplay).

HCG dan GnRH: Hormonal Optimization untuk Fertilitas dan Libido

FERTILITAS MALE: testosterona required spermatogenesis (sperm production); but exogenous testosterone SUPPRESSES spermatogenesis (paradox—high testosterona inhibit FSH via feedback, FSH critical sperm production). HCG (Human Chorionic Gonadotropin): LH analog, stimulate testis testosterone production DIRECTLY (bypass feedback). GnRH (Gonadotropin-Releasing Hormone): releases LH+FSH pulsatility (true restoration hypothalamic-pituitary-gonadal axis). PROTOKOL MALE FERTILITY: HCG 250-500 IU 3x/minggu (testosterona maintenance spermatogenesis) + GnRH pulso 0.1-0.5 mcg 2-3x/minggu (FSH stimulation spermatogenesis). GnRH timing KRITIK: pulse (not constant infusion)—pulsatile GnRH → LH+FSH pulse (mimic natural physiology); continuous GnRH → paradoxical suppression (desensitization pituitary). DOSIS HCG: 250-500 IU adalah sub-maximal (berbeda 1000+ IU performance enhancement athletes—yang suppress spermatogenesis paradoxically via negative feedback testosterone elevation). TIMELINE SPERMATOGENESIS: sperm production adalah 74-hari cycle; HCG efek spermatogonia 2-3 bulan kontinuo untuk measurable sperm improvement (swim velocity, morphology). FERTILITY TESTING: semen analysis baseline + 3 bulan (sperm count, motility, morphology), testosterona level baseline + 4 minggu (HCG efficacy). FEMALE FERTILITY: GnRH pulsatile therapy restore LH surge (ovulation trigger) di anovulation, primary hypogonadism. DOSIS FEMALE GnRH: 0.5-1.5 mcg every 90 minuto intranasal atau inyectable (mimic endógeno GnRH pulse). TIMELINE: ovulation restoration 2-3 months, pregnancy potential optimal 3-6 bulan kontinuo therapy. KOMBINASI FERTILITY: HCG + GnRH + BPC-157 (endothelial reproductive organs). MONITORING: semen analysis, LH/FSH/testosterona (male), LH surge detection (female), ultrasound follicular tracking (female).

Desire and Satisfaction: Comprehensive Sexual Health Protocol

PROTOKOL SEXUAL HEALTH COMPREHENSIVE: MALE SEXUAL DYSFUNCTION: (1) ED (mechanical/vascular): PT-141 (central arousal) + BPC-157 (endothelial, penile hemodynamics—nitrogen oxide, cavernosal tissue). (2) LOW LIBIDO (desire): HCG 250-500 IU 3x/minggu (testosterona), Semax 250mcg intranasal (dopamine-driven motivation), oxitocina 10-20 IU diario baseline (bonding + satisfaction). (3) ANORGASMIA (delayed ejaculation): Selank 250mcg (serotonin—serotonin excess delay ejaculation, Selank modulate), oxytocina pre-coito (orgasm amplification). FEMALE SEXUAL DYSFUNCTION: (1) AROUSAL DISORDER (FSAD): PT-141 0.5mg pre-coito (central arousal), GLP-1 bajo-dosis (cardiovascular female genitalia perfusion), BPC-157 (endothelial clitoral tissue). (2) LOW LIBIDO (HSDD): HCG 10-50 IU 3x/minggu (minimal testosterona boost, insufficient dosis spermatogenesis concern pero sufficient libido), OR prasterone DHEA 25-50mg diario (precursor testosterone + estrogen balance), oxitocina 10-20 IU diario. (3) ANORGASMIA (female): oxytocina 10 IU pre-coito (orgasm intensity), Selank 250mcg (mood, arousal context), clitoral BPC-157 topical cream 500mcg (local endothelial + nerve sensitivity). RELATIONSHIP ENHANCEMENT (non-dysfunction): oxytocina 10-20 IU intranasal ambos partners diario (bonding, satisfaction 40-50% improvement), PT-141 0.5mg pre-coito monthly/weekly (novelty arousal, desire maintenance long-term relationship), comunicasi + intimacy prioritas (peptidos complementary, tidak substitute psychological intimacy). TIMELINE ESPERADO: PT-141 onset minutos (acuto). HCG/GnRH onset 4-6 minggu (hormonal restoration). Oxytocina bonding 4-12 minggu (pair-bonding neuroplasticity). Sexual satisfaction improvement typically 2-8 minggu kombinasi protocol.

Hallazgos Clave

Productos relacionados

Más artículos en Guías Prácticas

Más artículos en Optimización Hormonal

Artículos relacionados

Términos del glosario

Preguntas frecuentes

¿Es PT-141 seguro con medicación cardiovascular?
Caution con antihypertensivos. PT-141 puede elevar presión arterial (melanocortin sympathetic activation). Si tomas antihypertensivo, monitorea presión post-PT-141 (15-30 minuto onset). Dosis lower (0.5mg) menor riesgo que 1mg. Contraindicated si uncontrolled hipertensión o cardiac arrhythmia. Consulta cardióloga.
¿Puedo combinar PT-141 con sildenafil (Viagra)?
Sí, pero sin estudios formales. PT-141 = central mechanism (arousal hypothalamus). Sildenafil = peripheral mechanism (erectile tissue vasodilation). Combinación teórica synergistic (central + peripheral). PERO: presión arterial risk aumento (ambos pueden affect presión—monitoreo crítico). Dosis conservadora: PT-141 0.5mg + sildenafil 25-50mg (no máximo dosis ambos). Iniciar prueba caution, consult physician.
¿Cuál es diferencia PT-141 vs. Viagra?
Viagra (sildenafil): PDE5 inhibitor, local erectile tissue vasodilation, 70-80% ED efficacy, onset 30-60 minuto, duration 4 horas. PT-141: melanocortin agonista, central arousal, 65-75% eficacia, onset 15-30 minuto, duration 4-6 horas. PT-141 advantage: arousal restoration (desire, not just mechanics), women-responsive, psicosexual-friendly. Viagra advantage: más available, cheaper, más studied long-term. Elección depende etiology ED (vascular vs. psicosexual) y preferencia.

Volver a la biblioteca de investigación